Nanobiotix S.A. (NBTX)
3.54
-0.08 (-2.21%)
At close: Mar 03, 2025, 2:57 PM
3.41
-3.70%
Pre-market: Mar 04, 2025, 09:25 AM EST
Company Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
The company was incorporated in 2003 and is headquartered in Paris, France.
Nanobiotix S.A.
| Country | FR |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Laurent Levy Ph.D. |
Contact Details
Address: 60 rue de Wattignies Paris, FR | |
| Website | https://www.nanobiotix.com |
Stock Details
| Ticker Symbol | NBTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001760854 |
| CUSIP Number | 63009J107 |
| ISIN Number | US63009J1079 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & Chief Executive Officer |
| Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication |
| Craig West CFA | Senior Vice President of Investor Relations |
| Dr. Leonard A. Farber M.D. | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board |
| Dr. Louis Kayitalire M.D. | Chief Medical Officer |
| Earl J. Bergey Ph.d. | Co-Founder |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | 6-K | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 29, 2025 | 6-K | Filing |
| Jan 21, 2025 | 6-K | Filing |
| Jan 10, 2025 | 6-K | Filing |
| Dec 17, 2024 | 6-K | Filing |
| Dec 16, 2024 | 6-K | Filing |
| Dec 12, 2024 | 6-K | Filing |
| Dec 11, 2024 | 6-K | Filing |
| Dec 09, 2024 | 6-K | Filing |